Background: The pathogenesis of psoriasis is complex, with a significant role suggested for pro-inflammatory mediators. There is strong evidence of an association between psoriasis and the metabolic syndrome (MetS), a cluster of cardiovascular risk factors, which impose a substantial disease burden. Objective: This study aimed to evaluate the prevalence of MetS and to examine the implications of disease severity, type 2 diabetes mellitus, and cardiovascular disease in a large cohort of Italian psoriatic patients representative of the whole population. Methods: This was a cross-sectional study involving 13 dermatological clinics in Italy. The primary study endpoint was a comparison of the prevalence of MetS between psoriatic patients and a non-psoriatic control group; secondary endpoints included the influence of psoriasis severity on the prevalence of MetS, and the relative prevalence and risk of type 2 diabetes mellitus and cardiovascular disorders. Results: A total of 720 patients were enrolled (n = 360 per group). The prevalence of MetS was 26.84 % in the psoriatic population and 15.16 % in the control population (p = 0.0001; adjusted odds ratio 1.96). MetS was associated with a greater degree of psoriasis severity, and the prevalence and risk of diabetes tended to be higher in psoriatic patients than in the control group. Conclusion: In the Italian population, the prevalence of MetS and associated comorbidities is elevated in patients with psoriasis compared with non-psoriatic subjects, as has been demonstrated in other countries. Our findings reinforce the importance of considering the implications of metabolic comorbidities in treating patients with psoriasis. © 2014 Springer International Publishing.

Metabolic syndrome prevalence in psoriasis: A cross-sectional study in the Italian population / Aurora, Parodi; Nicola, Aste; Camilla, Calvieri; Cantoresi, Franca; Carlesimo, Marta; Paolo, Fabbri; Giorgio, Filosa; Antonia, Galluccio; Paolo, Lisi; Giuseppe, Micali; Potenza, Concetta; Richetta, Antonio Giovanni; Marco, Simonacci; Piergiusto, Trevisan; Giancarlo, Valenti; Calvieri, Stefano. - In: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. - ISSN 1175-0561. - 15:4(2014), pp. 371-377. [10.1007/s40257-014-0074-8]

Metabolic syndrome prevalence in psoriasis: A cross-sectional study in the Italian population

CANTORESI, Franca;CARLESIMO, Marta;POTENZA, Concetta;RICHETTA, Antonio Giovanni;CALVIERI, Stefano;CALVIERI, CAMILLA;Fabbri, Paolo Maria
2014

Abstract

Background: The pathogenesis of psoriasis is complex, with a significant role suggested for pro-inflammatory mediators. There is strong evidence of an association between psoriasis and the metabolic syndrome (MetS), a cluster of cardiovascular risk factors, which impose a substantial disease burden. Objective: This study aimed to evaluate the prevalence of MetS and to examine the implications of disease severity, type 2 diabetes mellitus, and cardiovascular disease in a large cohort of Italian psoriatic patients representative of the whole population. Methods: This was a cross-sectional study involving 13 dermatological clinics in Italy. The primary study endpoint was a comparison of the prevalence of MetS between psoriatic patients and a non-psoriatic control group; secondary endpoints included the influence of psoriasis severity on the prevalence of MetS, and the relative prevalence and risk of type 2 diabetes mellitus and cardiovascular disorders. Results: A total of 720 patients were enrolled (n = 360 per group). The prevalence of MetS was 26.84 % in the psoriatic population and 15.16 % in the control population (p = 0.0001; adjusted odds ratio 1.96). MetS was associated with a greater degree of psoriasis severity, and the prevalence and risk of diabetes tended to be higher in psoriatic patients than in the control group. Conclusion: In the Italian population, the prevalence of MetS and associated comorbidities is elevated in patients with psoriasis compared with non-psoriatic subjects, as has been demonstrated in other countries. Our findings reinforce the importance of considering the implications of metabolic comorbidities in treating patients with psoriasis. © 2014 Springer International Publishing.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/568333
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 32
social impact